-
The fifth batch of national procurement and 6 provinces announced the implementation date!
Time of Update: 2021-09-12
TibetTibetOn August 31, the Tibet Autonomous Region Medical Insurance Bureau issued the "Notice on the Implementation of the Fifth Batch of Centralized Procurement by National Organizations and the Online Procurement of Drugs Selected in the Centralized Procurement of the "Eight Provinces and Two Districts" Inter-provincial Alliance".
-
New crown vaccine sales PK: Coxing Zhongwei's half-year profit may exceed 45 billion yuan
Time of Update: 2021-09-12
According to this estimate, Zhifeilongkoma may rely on the new crown vaccine to achieve a revenue of over 5 billion yuan and a net profit of nearly 3.
Fosun Pharma’s semi-annual report shows that during the reporting period, Fubitai achieved revenue of over 500 million yuan.
-
2021 China Agriculture and Forestry Waste Resource Fermentation Technology Development and Application Seminar
Time of Update: 2021-09-12
"2021 China Agriculture and Forestry Waste Resource Fermentation Technology Development and Application Seminar"Invitation cardIn 2021, the Ministry of Agriculture and Rural Affairs and the National
-
The State Food and Drug Administration and the General Administration of Customs: agreed to add Changchun Air Port as a drug import port
Time of Update: 2021-09-12
The content is as follows: Each port drug administration, each port drug inspection station, the Guangdong branch of the General Administration of Customs, Tianjin and Shanghai special offices, and all directly affiliated customs: Approved by the State Council, it was agreed to add Changchun Airport as a drug import port .
-
Sufficient supply of selected products in centralized procurement of coronary stents by national organizations
Time of Update: 2021-09-12
Xinhua News Agency, Beijing, September 6 (Reporter Peng Yunjia) According to the latest news from the National Organization's Joint Purchasing Office for High-Value Medical Consumables, the overall supply of selected coronary stents is stable, and the overall supply of various types of stents exceeds the procurement demand .
-
Luoxin Pharmaceutical: 5 drugs of its subsidiaries have been approved by the U.S. FDA
Time of Update: 2021-09-12
ANDA number: 206532Ipratropium bromide is an anticholinergic drug, which can prevent the increase of intracellular cyclo-guanylic acid phosphate caused by the interaction between acetylcholine and muscarinic receptors on bronchial smooth muscles, and has lung bronchiectasis effects .
-
Spend nearly 300 million US dollars!
Time of Update: 2021-09-12
The seamless integration of the iPSC platform and Evotec's proven small molecule discovery and development capabilities has enabled EVT8683 to go from cell-based phenotypic screening to successful IND filing in only 5 years .
-
Exploring the medical insurance payment standards...Jiangsu pharmaceutical online upgrade!
Time of Update: 2021-09-12
Key point 2: Behind the promotion of pharmacies purchasing on the platform is the change in the provincial medical insurance data catalog It is worth noting that in this draft of the opinion, it is particularly emphasized that all public medical institutions in Jiangsu Province (including military medical institutions in the Soviet Union, the same below) should use the medicines in the Jiangsu Sunshine Procurement Platform for bargaining purchases, open transactions, and exhaustion.
-
Listed pharmacy PK: Dashenlin is the most profitable, Yifeng has the fastest growth rate...
Time of Update: 2021-09-12
The largest growth rate among the six major chains; the last member of the "500 million club" is Yifeng Pharmacy, with a net profit of 505 million yuan, an increase of 25.
-
How to deal with the national procurement rules for the centralized procurement of Chinese patent medicines?
Time of Update: 2021-09-12
Unlike generic drugs, price reduction will not be the first choice, but to further promote the supply-side reform of Chinese patent medicine companies through national procurement, promote the survival of the fittest by related companies, further concentrate production capacity, and improve product quality; the second is to reduce prices .
-
The detailed list is here!
Time of Update: 2021-09-12
According to the WeChat official account of the Spring and Autumn Period, as of September 6, 2021, there are a total of 47 chemical drugs that have a high probability of entering the sixth batch of centralized procurement, of which the most reviewed company is omeprazole sodium for injection, with 13 companies , Tenofovir fumarate tablets and Memantine hydrochloride tablets have 12 reviewed companies, ranking second .
-
Jiangxi plans to collect 10 varieties of piperacillin, somatostatin, lactulose, etc.
Time of Update: 2021-09-12
# To determine the selected company ## To determine the selected company #The procurement of 10 varieties in Jiangxi Province this time adopts a combination of economic and technical standard review and commercial standard review.
-
Up to 200% CCTV exposed the price increase of Chinese medicinal materials
Time of Update: 2021-09-12
And this time specifically, the perennial low prices have led to a decrease in the enthusiasm of pharmaceutical farmers and thus reduced production, the high standards of the new pharmacopoeia drive price increases, the epidemic situation, and the impact of disasters are the main factors mentioned .
-
Yiling Pharmaceutical's new research drug Yishen Yangxin Anshen Tablets obtained drug registration certificate
Time of Update: 2021-09-12
Yishen Yangxin Anshen Tablets is the 12th innovative Chinese medicine with intellectual property rights independently developed by Ling Pharmaceutical .
-
Finding doctors and medicines is more convenient 20 Beijing hospitals carry out online diagnosis and treatment services
Time of Update: 2021-09-12
(over) Medical Network News, September 7 In order to facilitate patients' medical treatment and combine diagnosis and treatment services under epidemic prevention and control, the Beijing Hospital Management Center said today that the center actively promotes the development of Internet diagnosis and treatment services in municipal hospitals, and carries out online follow-up consultations for some common diseases and chronic diseases.
-
When the centralized procurement of biopharmaceuticals is on the agenda, how should pharmaceutical companies deploy?
Time of Update: 2021-09-12
For example, on July 15-16, 2020, relevant departments of the National Medical Security Administration held a symposium to listen to expert opinions and suggestions on the centralized procurement of biological products (including insulin) and Chinese patent medicines, study and improve procurement policies in related fields, and promote procurement methods Reform .
-
The clinical trial application of Ganlai FXR agonist in the treatment of primary biliary cholangitis was accepted by NMPA
Time of Update: 2021-09-12
On September 6, Gan Lai Pharmaceutical, a wholly-owned subsidiary of Golly Pharmaceuticals, announced that the clinical trial application of ASC42 for the treatment of patients with primary biliary cholangitis (PBC) has been accepted by the State Food and Drug Administration of China .
-
Hengrui Medicine's SHR-1701 injection and bevacizumab injection were approved for clinical trials
Time of Update: 2021-09-12
SHR-1701 injection has carried out a number of solid tumor clinical trials in China and a phase I clinical trial in Australia .
-
Qilu Pharmaceutical's PD-L1/4-1BB double antibody was approved for clinical use
Time of Update: 2021-09-12
On September 7, the official website of CDE showed that Qilu Pharmaceutical's PD-L1/4-1BB double antibody QLF31907 was approved for clinical use .
From: CDE official websiteQilu Pharmaceutical has deployed more than ten bio-innovative drugs, including monoclonal antibodies, double antibodies, and ADCs .
Qilu Pharmaceutical Bio-innovative Drug PipelineFrom: Insight database
-
AstraZeneca Ultomiris receives EU approval for the treatment of PNH in children and adolescents
Time of Update: 2021-09-12
This time, the European Commission’s decision to approve Ultomiris was mainly based on the interim results of a phase III clinical trial conducted on children and adolescents with PNH, which proved the safety and effectiveness of Ultomiris in these patients .
